CIHR Operating Grant : Canadian Pediatric COVID-19 Research Platform
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: inquire with unit
Memorial Deadline: Thursday 10th, February 2022
External Deadline: Tuesday 15th, February 2022
Description
This funding opportunity is part of the Government of Canada’s continued response to address the health challenges of the COVID-19 pandemic. The SARS-Co-V2 (COVID-19) pandemic has had dramatic effects on children and families in Canada. School closures, parental work from home measures, virtual classroom learning and the effects of COVID-19 infections in children (e.g., myocarditis, multisystem inflammatory syndrome in children [MIS-C], post-COVID-19 condition, etc.) have all taken their toll on the health, well-being and social development of children in Canadian. The development of vaccines and their widespread use in Canada has resulted in optimism that the return to normal (or near normal) life for families is within reach.
The vaccine development and worldwide roll-out has been a remarkable example of the power of collaborative science. Within a year of the declaration of a global pandemic by the World Health Organization, multiple vaccines were developed and, using rigorous large-scale vaccine trials, effectiveness and relative safety of the vaccines were demonstrated. Vaccine distribution and immunization started in December 2020 with elderly Canadians and front-line health care workers. This was followed by national and international widespread vaccination programs for adults. Trials for diverse children aged 12-17 and 5-11 followed rapidly thereafter in an effort to control the pandemic in one of the largest remaining viral reservoirs. For children ages 12-17, Canada started its vaccination program in June 2021. For children ages 5-11, Canada started its vaccination program in December 2021.
Collaborative Research Projects
Applications must include at least two relevant, high-quality, and appropriate collaborative research projects (examples of topics including but not limited to vaccine- and infection-related myocarditis, lung effects of COVID-19, long COVID-19 conditions, and/or other relevant resultant conditions) that may be scaled up quickly, and which respond to identified gaps and priority areas by the Platform.
Partner Linkage Tool
CIHR is providing a linkage tool that is intended to facilitate connections and collaborations (domestically and internationally) should there be interest. This is not a mandatory tool. Information is provided on a volunteer basis and does not confer any advantages in the evaluation and funding of applications. Please note that potential applicants are not required to use the linkage tool or contact those who have submitted their information.
If you would like to use this tool, please complete a short form. The information you provide will appear on a public CIHR web page.
Role and Contributions of Applicant Partners
CIHR recognizes that a broad range of partners may be relevant to this opportunity and it is expected that applicant(s) describe the role of all applicant partners and how/if they will contribute to research and research related activities. Any consideration of risk, including conflict of interest, should also be explained, as appropriate.
Funds Available
CIHR and partner(s) financial contributions for this initiative are subject to availability of funds. Should CIHR or partner(s) funding levels not be available or are decreased due to unforeseen circumstances, CIHR and partner(s) reserve the right to reduce, defer or suspend financial contributions to grants received as a result of this funding opportunity.
- The total amount available for this funding opportunity is up to $6,700,000, enough to fund one (1) Canadian Pediatric COVID-19 Research Platform for a term of two (2) years with the possibility for renewal based on the evolution of the pandemic.
- Of this amount:
- A maximum of $1,675,000 can be allocated for the establishment of the Collaborating Centre (CC); and
- The remaining total is designed to support the 13 or more Collaborating Site leads, guided by a fair and transparent volume- and/or activity-based formula.
For more information on the appropriate use of funds, refer to Allowable Costs.
For more information click here.